MorphoSys AG (NASDAQ:MOR) Q3 2023 Earnings Conference Call March 14, 2024 8:00 AM ET
Company Participants
Jean-Paul Kress - Chief Executive Officer
Tim Demuth - Chief Research and Development Officer
Lucinda Crabtree - Chief Financial Officer
Julia Neugebauer - Head of Investor Relations
Conference Call Participants
Derek Archila - Wells Fargo
Xian Deng - UBS
Operator
Good afternoon, ladies and gentlemen. Welcome and thank you for joining MorphoSys Full Year 2023 Results and Business Update Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. The presentation will be followed by a question-and-answer session. [Operator Instructions].
Be it my pleasure to turn the conference over to Julia Neugebauer. Please go ahead, ma'am.
Julia Neugebauer
Ladies and gentlemen, good afternoon and good morning. My name is Julia Neugebauer, Head of Investor Relations at MorphoSys's, and it is my pleasure to welcome you to our fourth quarter and full year 2023 financial results conference call.
Joining me in the call today are Jean-Paul Kress, our Chief Executive Officer, Tim Demuth, our Chief Research and Development Officer; and Lucinda Crabtree, our Chief Financial Officer.
Additional information regarding the proposed acquisition of MorphoSys by Novartis will be filed with the United States Securities and Exchange Commission over the coming weeks, and we encourage investors to review this information when it becomes available.
I'd also like to remind you that some of the statements made during the call today are forward-looking statements, including statements regarding our development plans and expectations for our compounds in our pipeline, as well as the development plans of our collaboration partners, and statements about the proposed acquisition of MorphoSys by Novartis.
These forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to differ materially, including those described in MorphoSys Form 20-F and annual report, all for the year ended December 31, 2023, and from time to time in other SEC documents of MorphoSys. It is important to keep in mind that our statements in this webcast speak as of today.
This is the agenda for today's call. Jean-Paul will begin with an overview of 2023 and an outlook for 2024. Tim will then share an update on our clinical development work with a focus on Pelabresib. And Lucy will follow this with a summary of our financial results. After our prepared remarks, we will open the call for your questions.